What are the recommended dosing titration, MRI monitoring schedule, and discontinuation criteria for Kisunla (donanemab‑azbt) in adults with early‑symptomatic Alzheimer disease (mild cognitive impairment or mild dementia with amyloid‑positive PET or CSF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Kisunla (Donanemab-azbt) Dosing and Monitoring Protocol for Early Alzheimer's Disease

Kisunla should be administered at 700 mg IV every 4 weeks for the first three infusions, then escalated to 1400 mg IV every 4 weeks thereafter, with mandatory MRI surveillance before the 2nd, 3rd, 4th, and 7th infusions to monitor for amyloid-related imaging abnormalities (ARIA). 1, 2

Patient Eligibility Requirements

Before initiating Kisunla, confirm the following diagnostic criteria:

  • Clinical stage: Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (Clinical Stages 3-4, MMSE 20-30) 2, 3
  • Biomarker confirmation: Documented amyloid pathology via amyloid PET or CSF assay (Aβ42/40 ratio or elevated p-tau) 1, 2
  • Functional status: CDR score of 0.5 (MCI) or 1.0 (mild dementia) with documented functional impairment 4, 2
  • Objective cognitive impairment: MoCA score ≤25 or comprehensive neuropsychological testing showing impairment in ≥1 cognitive domain 4

Critical caveat: Kisunla is NOT indicated for cognitively unimpaired individuals with positive biomarkers alone, even if they have preclinical amyloid pathology 4

Dosing Titration Schedule

The FDA-approved dosing regimen follows a two-phase approach 1:

  • Phase 1 (Infusions 1-3): 700 mg IV every 4 weeks
  • Phase 2 (Infusion 4 onward): 1400 mg IV every 4 weeks
  • Infusion duration: Approximately 30 minutes per infusion 1
  • Missed dose management: Resume at the same dose as soon as possible, maintaining the 4-week interval 1

Pre-Treatment Safety Assessment

Mandatory Baseline Evaluation

  • Baseline MRI: Obtain within 12 months prior to first infusion to assess for pre-existing ARIA and vascular pathology 1, 2
  • APOE genotyping: Required to stratify ARIA risk (APOE ε4 carriers have higher risk) 2
  • Exclusion criteria on MRI: >4 cerebral microbleeds, cortical superficial siderosis, or major vascular contribution to cognitive impairment 2

MRI Monitoring Schedule for ARIA Surveillance

Mandatory surveillance MRIs must be obtained at the following timepoints 1, 2:

  1. Before 2nd infusion (approximately week 4)
  2. Before 3rd infusion (approximately week 8)
  3. Before 4th infusion (approximately week 12)
  4. Before 7th infusion (approximately week 24)
  5. Before 12th infusion in higher-risk individuals (APOE ε4 carriers) 2
  6. Any time ARIA is clinically suspected (headache, confusion, visual disturbances, seizures) 1, 2

Common pitfall: Failure to obtain pre-infusion MRIs can result in undetected ARIA, which occurred in 24-30.5% of treated patients in clinical trials 5, 6

ARIA Management and Dosing Interruption Criteria

ARIA-E (Edema/Effusion) Management 1

Asymptomatic ARIA-E:

  • Mild: May continue dosing at current schedule
  • Moderate: Suspend dosing until radiographic resolution
  • Severe: Suspend dosing until radiographic resolution

Symptomatic ARIA-E:

  • Mild symptoms: May continue based on clinical judgment for mild ARIA-E; suspend for moderate/severe ARIA-E
  • Moderate/severe symptoms: Suspend dosing regardless of ARIA-E severity

ARIA-H (Hemosiderin Deposition) Management 1

Asymptomatic ARIA-H:

  • Mild: May continue dosing
  • Moderate or severe: Suspend dosing until radiographic stabilization

Symptomatic ARIA-H:

  • Any severity: Suspend dosing until radiographic stabilization

Intracerebral hemorrhage >1 cm: Suspend dosing until radiographic stabilization; use clinical judgment regarding resumption 1

Resumption Criteria

  • Follow-up MRI: Obtain 2-4 months after initial ARIA identification to assess resolution or stabilization 1
  • Clinical resolution: Symptoms must resolve before resuming treatment 1
  • Permanent discontinuation: Consider if severe or recurrent ARIA occurs 1

Treatment Discontinuation Criteria

Amyloid Clearance-Based Discontinuation

Consider stopping Kisunla when amyloid plaques are reduced to minimal levels 1, 2:

  • Timing: Typically assessed at 12-18 months after treatment initiation 2
  • Confirmation method: Amyloid PET showing plaque level <24.1 centiloids 1
  • Clinical trial data: In TRAILBLAZER-ALZ studies, patients achieving amyloid clearance were transitioned to placebo in a blinded manner 1, 6

This represents a unique feature of donanemab compared to other anti-amyloid therapies—treatment can be finite rather than indefinite once therapeutic goal is achieved 2, 7

Safety-Based Discontinuation

Permanently discontinue Kisunla for 1, 2:

  • Severe or life-threatening ARIA that does not resolve
  • Intracerebral hemorrhage >1 cm with clinical deterioration
  • Recurrent symptomatic ARIA despite dose interruptions
  • Treatment-related serious adverse events

Important safety note: Three deaths in clinical trials were considered treatment-related, primarily associated with ARIA complications 6

Additional Implementation Requirements

  • Multidisciplinary team: Treatment requires specialized teams trained in ARIA recognition and management 8, 4
  • CMS registry enrollment: Required for Medicare reimbursement 8, 4
  • Shared decision-making: Discuss risks (24-30.5% ARIA rate), benefits (slowing of cognitive decline by 3.25 points on iADRS at 76 weeks), and treatment burden with patients and caregivers 2, 6

Practical consideration: The intensive monitoring schedule and ARIA management requirements necessitate close collaboration between primary care, neurology, radiology, and infusion services 8

References

Research

Donanemab: Appropriate use recommendations.

The journal of prevention of Alzheimer's disease, 2025

Research

Donanemab: First Approval.

Drugs, 2024

Guideline

Donanemab Therapy Eligibility Criteria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease.

Journal of basic and clinical physiology and pharmacology, 2024

Research

Donanemab in Early Alzheimer's Disease.

The New England journal of medicine, 2021

Guideline

Kisunla Treatment for Alzheimer's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is Kisunla (donanemab) and what are its adverse effects and safety considerations?
What are the indications for Kisunla (donanemab‑azbt) in adult patients with early symptomatic Alzheimer’s disease, specifically those with mild cognitive impairment or mild dementia and confirmed cerebral amyloid pathology?
What is the recommended infusion protocol for donanemab (Kisunla) in Alzheimer's disease, including dose, infusion rate, premedication, MRI monitoring schedule, and management of ARIA?
What are the fatigue side effects of Leqembi (lecanemab)?
In older adults with early symptomatic Alzheimer’s disease, does Kisunla (donanemab‑azbt) stop disease progression?
In a patient with suspected acute cholecystitis and an elevated white‑blood‑cell count, what does the leukocytosis signify and how should the patient be evaluated and managed?
Is unilateral leg swelling normal after a lumbar laminectomy in a young healthy patient?
After moderate exercise, why does my perfusion index (PI) increase to about 12 while my oxygen saturation (SpO₂) decreases to approximately 95 % and the pulse‑oximeter waveform becomes narrower with reduced area under the curve?
How should I evaluate and manage a patient with severely elevated urine calcium (hypercalciuria)?
In older adults with early symptomatic Alzheimer’s disease, does Kisunla (donanemab‑azbt) stop disease progression?
What is the preferred oral antibiotic for acute bacterial sinusitis in an adult with chronic kidney disease stage 3 (estimated glomerular filtration rate 30–59 mL/min) and a documented amoxicillin allergy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.